N¹-(3-methoxybenzyl)-N²,N²-dimethylethane-1,2-diamine | 827328-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N¹-(3-methoxybenzyl)-N²,N²-dimethylethane-1,2-diamine
• 英文别名: [2-(Dimethylamino)ethyl][(3-methoxyphenyl)methyl]amine；N-[(3-methoxyphenyl)methyl]-N',N'-dimethylethane-1,2-diamine
• CAS: 827328-29-0
• 化学式: C₁₂H₂₀N₂O
• mdl: MFCD07364979
• 分子量: 208.304
• InChiKey: XMQLSZFTTPDIRP-UHFFFAOYSA-N

物化性质

• 沸点：
  298.1±20.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N¹-(3-methoxybenzyl)-N²,N²-dimethylethane-1,2-diamine 在 四(三苯基膦)钯 、 双氧水 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 二甲基亚砜 为溶剂， 反应 19.0h， 生成 3'-(3-(2-(dimethylamino)ethyl)-3-(3-methoxybenzyl)ureido)-[1,1'-biphenyl]-4-carboxamide
  参考文献：
  名称：

  一种联苯甲酰胺脲类化合物及其制备方法和应用

  摘要：

  本发明属于医药技术领域，尤其是肿瘤相关的疾病治疗领域，其中涉及一种联苯甲酰胺脲类化合物及其制备方法和应用。为了解决现有技术ROCK抑制剂效果仍有待提高的问题，本发明提出一种式(I)联苯甲酰胺脲类化合物：通过优势片段杂合的设计策略制备了新型联苯甲酰胺脲类ROCKI抑制剂，使其能同时伸入靶标关键结合区域(A口袋和D口袋)来提高与的靶标亲合力，进而改善对ROCK的抑制效果和抗肿瘤效果。

  公开号：

  CN112961081B
• 作为产物：
  描述：

  3-甲氧基苯甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 1.25h， 生成 N¹-(3-methoxybenzyl)-N²,N²-dimethylethane-1,2-diamine
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors

  摘要：

  RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (similar to 7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.

  DOI：

  10.1021/jm400062r

文献信息

• [EN] CXCR7 RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE CXCR7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014191929A1

  公开（公告）日：2014-12-04

  The present invention relates to derivatives of formula (I) Formula (I) wherein (R1)n, R 2a, R 2b, R 3a, R 3b, R 4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及公式（I）的衍生物 公式（I）其中（R1）n，R 2a，R 2b，R 3a，R 3b，R 4，L1，L2，X，Y 和 Ar1 如描述中所述，其制备方法，其药学上可接受的盐，以及其作为药物的用途，含有一个或多个公式（I）化合物的药物组合物，特别是其作为CXCR7受体调节剂的用途。
• [EN] BICYCLIC HETEROARYLS AS KINASE INHIBITORS<br/>[FR] HÉTÉROARYLES BICYCLIQUES FORMANT INHIBITEURS DE LA KINASE
  申请人：FENG YANGBO

  公开号：WO2011050245A1

  公开（公告）日：2011-04-28

  The invention is directed to heteroaryl compounds useful as inhibitors of various kinase enzymes. In various embodiments, the invention provides a heteroaryl compound having inhibitory bioactivity with respect to a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Flt kinase, an Aurora kinase, or a Src kinase, or any combination thereof. Compounds of the invention include bicyclic heteroaryl compounds of formula (I), which can contain a bridging nitrogen atom at a ring junction. The invention further provides methods of synthesis of compounds of the invention, pharmaceutical compositions, pharmaceutical combinations, and methods of treatment of malconditions using compounds of the invention.

  该发明涉及对各种激酶酶的抑制剂作为杂环芳基化合物的用途。在各种实施形式中，该发明提供了一种具有抑制生物活性的杂环芳基化合物，该生物活性与Rho激酶、AKT激酶、p70S6K激酶、LIM激酶、IKK激酶、Flt激酶、Aurora激酶或Src激酶或其任意组合相关。该发明的化合物包括具有式(I)的双环杂环芳基化合物，该化合物在环的连接处可以含有一个桥接氮原子。该发明还提供了合成该发明化合物的方法、药物组合物、药物组合以及使用该发明化合物治疗病症的方法。
• [EN] UREA AND CARBAMATE COMPOUNDS AND ANALOGS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS D'URÉE ET DE CARBAMATE ET ANALOGUES UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：FENG YANGBO

  公开号：WO2010036316A1

  公开（公告）日：2010-04-01

  The invention is directed to compounds that can inhibit the bioactivity of one or more kinases such as any of Rho kinases, PKB (Akt) kinases, p70S6K kinase, LIM kinases, or IKK kinases, to methods of use of those compounds, and to methods of preparation of those compounds The inventive compounds can be used In the treatment of a variety of medical malconditions.

  该发明涉及可以抑制一个或多个激酶的生物活性的化合物，如Rho激酶、PKB（Akt）激酶、p70S6K激酶、LIM激酶或IKK激酶中的任何一个，以及这些化合物的使用方法和制备方法。这些创新的化合物可用于治疗各种医疗疾病。
• CXCR7 RECEPTOR MODULATORS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160107997A1

  公开（公告）日：2016-04-21

  The present invention relates to derivatives of formula (I) wherein (R 1 ) n , R 2a , R 2b , R 3a , R 3b , R 4 , L 1 , L 2 , X, Y and Ar 1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.

  本发明涉及公式（I）的衍生物，其中（R1）n，R2a，R2b，R3a，R3b，R4，L1，L2，X，Y和Ar1如描述中所述，其制备方法，其制备的药学上可接受的盐，以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，尤其是它们作为CXCR7受体调节剂的用途。
• Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (Part-II)
  作者：E. Hampton Sessions、Sarwat Chowdhury、Yan Yin、Jennifer R. Pocas、Wayne Grant、Thomas Schröter、Li Lin、Claudia Ruiz、Michael D. Cameron、Philip LoGrasso、Thomas D. Bannister、Yangbo Feng

  DOI：10.1016/j.bmcl.2011.09.084

  日期：2011.12

  Therapeutic interventions with Rho kinase (ROCK) inhibitors may effectively treat several disorders such as hypertension, stroke, cancer, and glaucoma. Herein we disclose the optimization and biological evaluation of potent novel ROCK inhibitors based on substituted indole and 7-azaindole core scaffolds. Substitutions on the indole C3 position and on the indole NH and/or amide NH positions all yielded potent and selective ROCK inhibitors (25, 42, and 50). Improvement of aqueous solubility and tailoring of in vitro and in vivo DMPK properties could be achieved through these substitutions. (C) 2011 Elsevier Ltd. All rights reserved.